NASDAQ$TYRA
Tyra Biosciences Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Tyra Biosciences reported Q2 2025, net loss of $45M.
For Q2 2025, Tyra Biosciences reported a net loss of $45M. The Form 10-Q discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net loss $45M.
- Tyra Biosciences highlights operating priorities and capital allocation.
- Tyra Biosciences highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
The filing discusses Tyra Biosciences's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed in MD&A.
Tailwinds
- Tyra Biosciences cites execution and demand supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
- Clinical-stage biotech companies face funding and trial execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro